Private Label Nexium OTC Buoys Perrigo As Pricing Trims Rx Revenues
This article was originally published in The Pink Sheet
Executive Summary
Perrigo's third-quarter launch of private label Nexium24HR was primary contributor of $13m in new product sales in North America.
You may also be interested in...
Perrigo's Next Private Label First Lands With Second Thoughts On Outlook
The launch of a private label version 24HR OTC heartburn treatment comes with Perrigo in need of another high-selling product to boost revenues in its core business, OTC private label. But analysts call for Perrigo to do more to grow in new markets.
Perrigo CEO Takes Faith In Rx Generics Business To Exit Door With Him
Private label OTC business is likely to be strengthened as Perrigo’s core, as CEO Hendrickson announces retirement shortly after hedge fund investor Starboard Value, pushing to divest the Rx business, built a five-seat block on Perrigo's board.
Private Label Competition For Zegerid OTC Sets Sail With Perrigo Launch
Perrigo's omeprazole and sodium bicarbonate capsules indicated for the treatment of frequent heartburn will bear labeling that has been through several updates since the first PPI became available OTC in 2004.